Covered recipient · General Payments record
LORETTA J NASTOUPIL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$353,462.22
- Reported across 285 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $10,460.00 | 8 |
| Food and Beverage | $433.04 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,985.00 | 5 |
| BeiGene USA, Inc. | $2,625.00 | 2 |
| Genmab U.S., Inc. | $2,250.00 | 1 |
| Merck Sharp & Dohme Corporation | $610.00 | 1 |
| Kite Pharma, Inc. | $211.01 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $113.65 | 1 |
| Genentech USA, Inc. | $98.38 | 3 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| BeiGene USA, Inc. | $375.00 | 07/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120865262 | CMS |
| BeiGene USA, Inc. | $2,250.00 | 07/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120865264 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 01/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101558817 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,730.00 | 02/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101558825 | CMS |
| E.R. Squibb & Sons, L.L.C. | $519.00 | 05/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101558836 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101558867 | CMS |
| E.R. Squibb & Sons, L.L.C. | $650.00 | 06/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101558844 | CMS |
| Genentech USA, Inc. | $31.78 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133055690 | CMS |
| Genentech USA, Inc. | $49.44 | 04/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133055682 | CMS |
| Genentech USA, Inc. | $17.16 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133055686 | CMS |
| Genmab U.S., Inc. | $2,250.00 | 01/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1126829012 | CMS |
| Kite Pharma, Inc. | $112.64 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128613581 | CMS |
| Kite Pharma, Inc. | $22.11 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128613611 | CMS |
| Kite Pharma, Inc. | $76.26 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128613605 | CMS |
| Merck Sharp & Dohme LLC | $610.00 | 06/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141563889 | CMS |
| Novartis Pharmaceuticals Corporation | $113.65 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086962970 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.